Royalty Pharma Boosts Board with Two Independent Directors

By Bobby Samwell • Thursday, July 17 15:30 • Permanent Link

Royalty Pharma PLC (NASDAQ: RPRX) has announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its board of directors, marking a significant move to enhance corporate governance. The addition of these two independent members increases independent representation on the board to greater than 90%.

Carole Ho, currently the Chief Medical Officer and Head of Development at Denali Therapeutics, brings 20 years of experience in the biopharma industry. She has a strong background in therapeutic development, having led development of therapeutics in neurology, immunology, ophthalmology, and infectious disease during her tenure at Genentech. Carole Ho holds an SB in biochemistry from Harvard University and an MD with honors in research from Weill Cornell Medicine.

Elizabeth (Bess) Weatherman, a seasoned investor with 35 years of experience across the healthcare industry, is a Special Limited Partner at Warburg Pincus LLC. She brings a deep understanding of capital markets, corporate governance, and medical innovation. Bess Weatherman holds a BA in English, summa cum laude and Phi Beta Kappa, from Mount Holyoke College and an MBA from the Stanford Graduate School of Business.

Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry. The company collaborates with innovators from academic institutions, research hospitals, and non-profits, as well as small and mid-cap biotechnology companies to leading global pharmaceutical companies. The company's portfolio includes royalties on more than 35 commercial products and 16 development-stage product candidates, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy. Following these announcements, the company's shares moved -0.23%, and are now trading at a price of $35.52. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.